Kirkham Tim C
School of Psychology, University of Liverpool, Liverpool, UK.
Int Rev Psychiatry. 2009 Apr;21(2):163-71. doi: 10.1080/09540260902782810.
The ability of Cannabis sativa to promote eating has been documented for many centuries, with the drug reported by its users to promote strong cravings for, and an intensification of the sensory and hedonic properties of food. These effects are now known to result from the actions of cannabinoid molecules at specific cannabinoid receptor sites within the brain, and to reflect the physiological role of their natural ligands, the endocannabinoids, in the control of appetite. Recent developments in the biochemistry and pharmacology of endocannabinoid systems have generated convincing evidence from animal models for a normal role of endocannabinoids in the control of eating motivation. The availability of specific cannabinoid receptor agonists and antagonists raises the possibility of improved therapies for disorders of eating and body weight: not only in the suppression of appetite to counter our susceptibility to the over-consumption of highly pleasurable and energy-dense foods; but also in the treatment of conditions that involve reduced appetite and weight loss. Here, we outline some of the findings of the past decade that link endocannabinoid function appetite control, and the possible clinical applications of that knowledge.
几个世纪以来,大麻促进进食的能力已有文献记载,其使用者称该药物会引发对食物的强烈渴望,并增强食物的感官和享乐特性。现在已知这些作用是由大麻素分子作用于大脑内特定的大麻素受体位点所致,也反映了其天然配体——内源性大麻素在控制食欲方面的生理作用。内源性大麻素系统生物化学和药理学的最新进展已从动物模型中获得了令人信服的证据,证明内源性大麻素在控制进食动机方面具有正常作用。特异性大麻素受体激动剂和拮抗剂的出现,为改善饮食和体重紊乱的治疗带来了可能性:不仅可以抑制食欲,以应对我们对高愉悦感和高能量食物过度消费的易感性;还可用于治疗食欲减退和体重减轻的病症。在此,我们概述过去十年中一些将内源性大麻素功能与食欲控制联系起来的研究发现,以及该知识可能的临床应用。